Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Tumorvirus-specific Vaccination Strategies

HPV L2 cross-protective vaccines

Hanna Seitz, PhD Student



Infections with human papilloma viruses present one of the main risk factors for the development of invasive cervix carcinoma. Two commercially available vaccines, Gardasil® and Cervarix®, based on so called virus-like-particles (VLPs) are able to induce neutralizing anti-L1 antibodies and are protective against infection by the two high risk HPV types 16 and 18. However, the vaccine induced anti-L1 antibodies are highly HPV type specific (for HPV 16 and 18) and do not effectively protect against other oncogenic HPVs. At least 15 HPV types have been causally linked to cervix carcinoma, and thus a broadly cross-neutralizing vaccine is desired. Interestingly, it has been found that antibodies against the HPV minor capsid protein L2 act cross-neutralizing against several HPV types. However, L2 suffers from a rather low immunogenicity compared to the more immunogenic L1. In collaboration with the University of Parma, vaccine antigens in which neutralizing L2 epitopes are inserted into the scaffold of bacterial thioredoxin were developed. These antigens are able to induce neutralizing responses much more efficiently compared to the L2 protein alone. It is the objective of the project to further improve antigen design, to investigate alternative scaffolds and to determine mechanisms of neutralization. Screening for optimized, immunogenic L2 epitope conformations will be performed using highly efficient and broadly cross-neutralizing L2 monoclonal antibodies.

to top
powered by webEdition CMS